Literature DB >> 21793073

MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer.

Kristine Glunde1, Lu Jiang, Siver A Moestue, Ingrid S Gribbestad.   

Abstract

MRS and MRSI are valuable tools for the detection of metabolic changes in tumors. The currently emerging era of molecular medicine, which is shaped by molecularly targeted anticancer therapies combined with molecular imaging of the effects of such therapies, requires powerful imaging technologies that are able to detect molecular information. MRS and MRSI are such technologies that are able to detect metabolites arising from glucose and choline metabolism in noninvasive in vivo settings and at higher resolution in tissue samples. The roles played by MRS and MRSI in the diagnosis of different types of cancer, as well as in the early monitoring of the tumor response to traditional chemotherapies, are reviewed. The emerging roles of MRS and MRSI in the development and detection of novel targeted anticancer therapies that target oncogenic signaling pathways or markers in choline or glucose metabolism are discussed.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793073      PMCID: PMC3146026          DOI: 10.1002/nbm.1751

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  187 in total

1.  On respiratory impairment in cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-08-10       Impact factor: 47.728

2.  Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method.

Authors:  R Katz-Brull; H Degani
Journal:  Anticancer Res       Date:  1996 May-Jun       Impact factor: 2.480

3.  Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density.

Authors:  Oliver Ganslandt; Andreas Stadlbauer; Rudolf Fahlbusch; Kyosuke Kamada; Rolf Buslei; Ingmar Blumcke; Ewald Moser; Christopher Nimsky
Journal:  Neurosurgery       Date:  2005-04       Impact factor: 4.654

Review 4.  Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism.

Authors:  Kristine Glunde; Natalie J Serkova
Journal:  Pharmacogenomics       Date:  2006-10       Impact factor: 2.533

Review 5.  3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy.

Authors:  S Ganapathy-Kanniappan; M Vali; R Kunjithapatham; M Buijs; L H Syed; P P Rao; S Ota; B K Kwak; R Loffroy; J F Geschwind
Journal:  Curr Pharm Biotechnol       Date:  2010-08       Impact factor: 2.837

6.  The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.

Authors:  Nada M S Al-Saffar; L Elizabeth Jackson; Florence I Raynaud; Paul A Clarke; Ana Ramírez de Molina; Juan C Lacal; Paul Workman; Martin O Leach
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

7.  Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas.

Authors:  Andreas Stadlbauer; Ewald Moser; Stephan Gruber; Rolf Buslei; Christopher Nimsky; Rudolf Fahlbusch; Oliver Ganslandt
Journal:  Neuroimage       Date:  2004-10       Impact factor: 6.556

Review 8.  Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond.

Authors:  Vadivel Ganapathy; Muthusamy Thangaraju; Puttur D Prasad
Journal:  Pharmacol Ther       Date:  2008-11-01       Impact factor: 12.310

Review 9.  Methodological standardization for a multi-institutional in vivo trial of localized 31P MR spectroscopy in human cancer research. In vitro and normal volunteer studies.

Authors:  F Arias-Mendoza; K Zakian; A Schwartz; F A Howe; J A Koutcher; M O Leach; J R Griffiths; A Heerschap; J D Glickson; S J Nelson; J L Evelhoch; H C Charles; T R Brown
Journal:  NMR Biomed       Date:  2004-10       Impact factor: 4.044

10.  Metabolic flux determination in C6 glioma cells using carbon-13 distribution upon [1-13C]glucose incubation.

Authors:  J C Portais; R Schuster; M Merle; P Canioni
Journal:  Eur J Biochem       Date:  1993-10-01
View more
  25 in total

1.  Choline kinase inhibition in rheumatoid arthritis.

Authors:  M Guma; E Sanchez-Lopez; A Lodi; R Garcia-Carbonell; S Tiziani; M Karin; J C Lacal; G S Firestein
Journal:  Ann Rheum Dis       Date:  2014-10-01       Impact factor: 19.103

2.  Peak-specific phase correction for automated spectrum processing of in vivo magnetic resonance spectroscopic imaging by using the multiscale approach.

Authors:  Xiaodong Zhang; Xiaoping Hu
Journal:  Bo Pu Xue Za Zhi       Date:  2014-03-05

Review 3.  Future technology insight: mass spectrometry imaging as a tool in drug research and development.

Authors:  D F Cobice; R J A Goodwin; P E Andren; A Nilsson; C L Mackay; R Andrew
Journal:  Br J Pharmacol       Date:  2015-05-05       Impact factor: 8.739

4.  RNAi-mediated knockdown of PFK1 decreases the invasive capability and metastasis of nasopharyngeal carcinoma cell line, CNE-2.

Authors:  Shuo Li; Peng He; Zhiwei Wang; Meng Liang; Wei Liao; Yili Huang; Mengshi Chi; Fei Liu; Nan Zen; Rongfei Su; Shulin Chen; Zhigang Liu; Haiyu Hong
Journal:  Cell Cycle       Date:  2021-01-06       Impact factor: 4.534

5.  Emerging findings of glutamate-glutamine imbalance in the medial prefrontal cortex in attention deficit/hyperactivity disorder: systematic review and meta-analysis of spectroscopy studies.

Authors:  Marcos Vinícius Vidor; Alana Castro Panzenhagen; Alexandre Ribeiro Martins; Renata Basso Cupertino; Cibele Edom Bandeira; Felipe Almeida Picon; Bruna Santos da Silva; Eduardo Schneider Vitola; Luis Augusto Rohde; Diego Luiz Rovaris; Claiton Henrique Dotto Bau; Eugênio Horácio Grevet
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-03-24       Impact factor: 5.270

6.  Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.

Authors:  Hui Mao; Erwin G Van Meir; Juliya Kalinina; Anne Carroll; Liya Wang; Qiqi Yu; Danny E Mancheno; Shaoxiong Wu; Frank Liu; Jun Ahn; Miao He
Journal:  J Mol Med (Berl)       Date:  2012-03-17       Impact factor: 5.606

7.  Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation.

Authors:  Brendon J Coventry; Martin L Ashdown
Journal:  Cancer Manag Res       Date:  2012-05-28       Impact factor: 3.989

8.  Radiotherapy planning using MRI.

Authors:  Maria A Schmidt; Geoffrey S Payne
Journal:  Phys Med Biol       Date:  2015-10-28       Impact factor: 3.609

9.  Non-invasive imaging for studying anti-angiogenic therapy effects.

Authors:  Josef Ehling; Twan Lammers; Fabian Kiessling
Journal:  Thromb Haemost       Date:  2013-02-14       Impact factor: 5.249

10.  Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.

Authors:  Siver A Moestue; Cornelia G Dam; Saurabh S Gorad; Alexandr Kristian; Anna Bofin; Gunhild M Mælandsmo; Olav Engebråten; Ingrid S Gribbestad; Geir Bjørkøy
Journal:  Breast Cancer Res       Date:  2013-02-28       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.